Teva Pharma (TEVA) Reports In-Line Q4 EPS

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.31, in-line with the analyst estimate of $1.31. Revenue for the quarter came in at $5.17 billion versus the consensus estimate of $5.17 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
• Skillsoft (SKIL) Tops Q2 EPS by 14c; Offers Guidance